Literature DB >> 25764631

In vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Visanu Thamlikitkul, Surapee Tiengrim, Chakrapong Seenama.   

Abstract

OBJECTIVE: To determine in vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii. MATERIAL AND
METHOD: The activity of polymyxin B was determined against 217 strains of carbapenem-resistant A. baumannii collected from different patients by standard agar dilution method and disk diffusion test using polymyxin B disk (300 units). The control strains were E. coli ATCC 25922 and P. aeruginosa ATCC 27853.
RESULTS: The MIC values and inhibition zone diameters of polymyxin B against the quality control bacteria were within the acceptable range. The MIC50 and MIC90 values of polymyxin B against 217 strains of carbapenem-resistant A. baumannii were 0.5 and 1 mg/l, respectively. If the susceptible MIC breakpoint of polymyxin B was ≤ 2 mg/l, 98.2% of carbapenem-resistant A. baumannii strains were susceptible to polymyxin B. If the susceptible MIC breakpoint of polymyxin B was ≤ 2 mg/l, the sensitivity and the specificity ofthe inhibition zone diameter of > 12 mm were 100% and 75%, respectively. The aforementioned diagnostic parameters gave positive predictive value of 99.5% and negative predictive value of 100% for predicting susceptibility of carbapenem-resistant A. baumannii to polymyxin B by disk diffusion test.
CONCLUSION: Polymyxin B was very active against carbapenem-resistant A. baumannii. The inhibition zone diameters of >12 mm was accurate enough to determine susceptibility of carbapenem-resistant A. baumannii topolymyxin B. Polymyxin B can be an alternative to or more preferable than colistin for therapy ofcarbapenem-resistant A. baumannii infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25764631

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  4 in total

1.  Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii.

Authors:  Nahid Madadi-Goli; Rezvan Moniri; Sareh Bagheri-Josheghani; Nilufar Dasteh-Goli
Journal:  Iran J Microbiol       Date:  2017-02

2.  Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand.

Authors:  Thundon Ngamprasertchai; Adhiratha Boonyasiri; Lantharita Charoenpong; Sireethorn Nimitvilai; Narisorn Lorchirachoonkul; Luksame Wattanamongkonsil; Visanu Thamlikitkul
Journal:  Infect Drug Resist       Date:  2018-08-20       Impact factor: 4.003

3.  A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.

Authors:  Qiong Lu; Hai-Hong Zhu; Guo-Hua Li; Ting-Ting Qi; Liang-Jun Ye; Xin-Qi Teng; Qiang Qu; Ge-Fei He; Jian Qu
Journal:  Front Med (Lausanne)       Date:  2021-02-09

Review 4.  Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.

Authors:  Suneel Kumar Garg; Omender Singh; Deven Juneja; Niraj Tyagi; Amandeep Singh Khurana; Amit Qamra; Salman Motlekar; Hanmant Barkate
Journal:  Crit Care Res Pract       Date:  2017-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.